Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It does not affect what you pay, and it never determines our rankings or which providers we cover. Read the full disclosure.

Status: Not covered — investigational drug

Will Retatrutide Be Covered by the CMS BALANCE Model?

By The RX Index Editorial Team — Last verified: June 1, 2026.

This is coverage education, not medical advice. Talk to a licensed clinician about whether any GLP-1 medication is right for you.

Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.

Short answer: no.

Retatrutide will not be covered by the CMS BALANCE Model — or the Medicare GLP-1 Bridge — right now. It can't be yet, and the reason is simpler than the rumors make it sound: retatrutide isn't FDA-approved, and both programs only pay for GLP-1 medicines the FDA has already cleared for weight management.

Quick decoder — four things getting tangled together online:

Retatrutide is Eli Lilly's experimental weight-loss drug. It hits three body signals at once (a “triple agonist”), which is why the trial numbers have been so big.
CMS is the federal agency that runs Medicare and Medicaid.
The BALANCE Model is a new CMS program that negotiates lower GLP-1 prices for people on Medicare and Medicaid.
The Medicare GLP-1 Bridge is a short-term program that gives eligible Medicare members certain GLP-1 drugs for a flat $50 a month.

Quick answer table

Your question	The answer today
Is retatrutide FDA-approved?	No — it's still in clinical trials
Is retatrutide covered by the CMS BALANCE Model?	No — it's not on the list
Is retatrutide in the Medicare GLP-1 Bridge?	No
Can you buy it legally right now?	No — only through a Lilly clinical trial
Could it be covered later?	Possibly, after FDA approval — not guaranteed
What can Medicare help with starting July 1, 2026?	The $50 Bridge (Foundayo, Wegovy, Zepbound KwikPen) if you qualify, or regular Part D for covered non-weight-loss uses

See which Medicare GLP-1 path may apply to you. Answer a few questions about your coverage, your state, and your health, and the free 60-second matcher points you to the most likely legal path to check next.

Take the free GLP-1 path quiz →

The honest part, said plainly

Great trial results do not create insurance coverage. Retatrutide may turn out to be the strongest weight-loss drug we've seen, and it would still not be covered by Medicare today — because coverage runs on FDA approval and program rules, not headlines. If you were hoping to wait a few months and have Medicare pay for retatrutide, that path does not exist right now.

Here's the hopeful flip side, and it's real: you are not stuck. A brand-new Medicare program launches July 1, 2026 that covers other GLP-1 drugs for $50 a month — drugs that are FDA-approved and already on the market. A lot of people asking about retatrutide and Medicare may turn out to qualify for it, if they meet the rules. So the smart move isn't to chase a drug you can't get. It's to find out, in a couple of minutes, what you can get.

Will retatrutide be covered by the CMS BALANCE Model right now?

No. Retatrutide is not covered by the CMS BALANCE Model, because it is not FDA-approved and is not on the model's covered-drug list. The BALANCE Model only includes GLP-1 medicines whose active ingredient the FDA has already approved for weight management. Retatrutide is still investigational — meaning it is being tested but has not been cleared for sale.

This is where it gets interesting, and where most pages stop short. CMS published the exact rules a drug must meet to be in the BALANCE Model. Retatrutide lines up with part of the checklist — but not the part that counts most right now.

To make the BALANCE list, a drug must clear three product tests

The right mechanism. It must act as a GIP, GLP-1, or glucagon receptor agonist — or any combination.
Strong enough results. It must reduce body weight by at least 9.5% on average, at an FDA-approved dose, in a clinical trial.
FDA approval — on time. Its active ingredient must already be FDA-approved for weight management, or expected to be approved by no later than January 1, 2027.

Where retatrutide stands

Retatrutide is a triple agonist that hits all three of those receptors, so it clears the mechanism test. In Lilly's TRIUMPH-1 trial, the 12 mg dose produced an average of 28.3% weight loss at 80 weeks — far above the 9.5% bar. So the size of the effect is more than enough.

Here's the wall. Test #2 doesn't just ask for 9.5% — it asks for 9.5% at an FDA-approved dose. Retatrutide has no FDA-approved dose, because it isn't approved at all. So it can't officially clear that test, it fails the FDA-approval test outright, and it misses the January 1, 2027 timing cutoff. Even FDA approval wouldn't be the finish line — CMS would still have to add retatrutide to the list, agree on a price with Lilly, and write the patient rules.

The one sentence to remember: Retatrutide could be a future coverage candidate, but it is not a covered CMS BALANCE drug today — and FDA approval is only the first of several doors it still has to walk through.

The Retatrutide CMS Coverage Gate Scorecard

Verified June 1, 2026. To be covered by BALANCE or the Bridge, retatrutide has to pass through several gates. Here's exactly where it stands on each one.

Coverage gate	What CMS requires	Retatrutide today	Status	What must change
Drug mechanism	GIP / GLP-1 / glucagon agonist (any combination)	Triple GIP/GLP-1/glucagon agonist	✅ Clears it	Nothing
Weight-loss results	≥ 9.5% avg body-weight reduction at an FDA-approved dose	28.3% avg at 80 weeks (12 mg) in TRIUMPH-1 -- but no FDA-approved dose exists	🟡 Beats the number; can't officially count yet	An FDA-approved dose has to exist first
FDA approval	Active ingredient approved for weight management	Not approved -- investigational	❌ Fails	FDA approval must happen
Approval timing	Approved (or expected) by Jan 1, 2027	No approval published; Lilly says availability depends on finishing trials	❌ Fails	Could only enter through a later CMS negotiation round
On the covered list	Named on the BALANCE / Bridge drug list	Not listed	❌ Fails	CMS adds it after approval
Maker participates	Manufacturer opts in and agrees on price	Lilly participates for its approved drugs; retatrutide terms unknown	❓ Unknown	Lilly and CMS would negotiate
Legal to obtain	Prescribable outside clinical trials	Clinical trials only	❌ Fails	Commercial launch after approval
You qualify	Meet BMI / condition / PA rules	No retatrutide path exists	-- N/A yet	Rules get written after a drug is listed

Read down that Status column and the picture is clear. Retatrutide isn't blocked because it's weak. It's blocked because it's early — stuck at the approval gates, not the science gates.

Not waiting around? See which GLP-1 path fits your situation now. It checks Medicare, Medicaid, and cash-pay routes in about a minute.

Take the free 60-second quiz →

What does the CMS BALANCE Model actually cover?

The BALANCE Model is a voluntary CMS program that negotiates lower GLP-1 prices for people on Medicare and Medicaid. Its current covered drugs are all formulations of Mounjaro, Ozempic, Rybelsus, and Wegovy, the KwikPen version of Zepbound, and the Foundayo (orforglipron) tablet — not retatrutide. It's voluntary for the manufacturers, the states, and the plans, so it does not guarantee coverage for any one person.

Drug	Active ingredient	On BALANCE list?	On Bridge list?
Mounjaro	tirzepatide	✅ All formulations	❌
Ozempic	semaglutide	✅ All formulations	❌
Rybelsus	semaglutide (pill)	✅ All formulations	❌
Wegovy	semaglutide	✅ All formulations	✅ All formulations
Zepbound	tirzepatide	✅ KwikPen only	✅ KwikPen only
Foundayo	orforglipron (pill)	✅ Tablet	✅ All formulations
Retatrutide	retatrutide	❌ Not listed	❌ Not listed

Source: CMS BALANCE Model and CMS Medicare GLP-1 Bridge, checked June 1, 2026.

BALANCE vs. the Bridge vs. regular Part D vs. Medicaid

These four things are not the same, and mixing them up is the #1 reason people get confused about retatrutide and Medicare. None of them cover retatrutide.

Program	Who it's for	What it does	Covers retatrutide?
Medicare GLP-1 Bridge	Eligible Medicare Part D members, nationwide	$50/month for certain weight-loss GLP-1s, July 1, 2026 -- Dec 31, 2027	No
BALANCE Model	Medicaid states (from May 2026); Medicare Part D plans later	Negotiates lower GLP-1 prices through 2031; Medicare access currently handled through the Bridge	No
Regular Medicare Part D	Medicare drug-plan members	May cover GLP-1s for covered non-weight-loss uses -- not weight loss	No (not approved at all)
Medicaid	Members in participating states	State-by-state GLP-1 coverage for weight management, rolling out in 2026	No

Timing note: Medicaid coverage under BALANCE can begin as early as May 2026 for states that join. For Medicare, the original plan had Part D plans joining BALANCE in January 2027 — but after too few insurers signed up, CMS extended the Bridge to a full 18 months (through December 31, 2027) to gather more data before Part D plans take part. In practice, the Medicare side of BALANCE may not arrive until around 2028, and the Bridge is the path in the meantime.

What does the Medicare GLP-1 Bridge cover instead?

The Medicare GLP-1 Bridge is a short-term CMS program that gives eligible Part D members certain FDA-approved weight-loss GLP-1s for a flat $50 a month, from July 1, 2026 through December 31, 2027. It covers all formulations of Foundayo and Wegovy, plus the KwikPen version of Zepbound. It does not cover retatrutide. You don't have to sign up — your doctor submits a prior authorization and a prescription to a central processor.

Bridge-covered drug	Your copay	Typical cash price it replaces	Formulation note
Foundayo (orforglipron pill)	$50/month flat	up to ~$349/month	All formulations
Wegovy (pill + injection)	$50/month flat	Wegovy pill up to ~$299/month	All formulations
Zepbound (KwikPen)	$50/month flat	up to ~$699/month	KwikPen only — single-dose vials and pens are not covered
Retatrutide	—	—	Not covered

The fine print the $50 headlines skip

⚠The $50 won't count toward your Part D deductible, the coverage gap, or your $2,100 yearly out-of-pocket cap.
⚠Extra Help (the low-income subsidy) can't be applied to Bridge drugs.
⚠It's temporary — it ends December 31, 2027.
✓The $50 is flat — it does not go up as your dose increases. Behind the scenes, drugmakers supply these at a net price of $245 a month; you still pay just $50.

Who qualifies for the Bridge?

A provider has to submit a prior authorization confirming the drug is for reducing and maintaining body weight alongside lifestyle changes, that you're 18 or older, and that you meet one of these CMS clinical paths:

▶BMI 35 or higher, or
▶BMI 30 or higher plus heart failure with preserved ejection fraction, uncontrolled high blood pressure, or chronic kidney disease stage 3a or higher, or
▶BMI 27 or higher plus prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.

One nuance worth knowing: CMS looks at your BMI at the time you first started GLP-1 therapy, not your BMI today. So if you began at a BMI of 37 and you're now at 34 because the medicine is working, you still qualify. Our Bridge eligibility guide walks through the BMI and condition rules in plain language.

Could retatrutide be added to BALANCE or the Bridge after FDA approval?

Maybe — but it's not automatic, and it's not soon. CMS has said it expects to reopen negotiations as new drugs reach the market, so retatrutide could become a candidate after FDA approval. But approval is just the first step. CMS, Lilly, and participating plans or states would all still have to agree on terms, and you'd still have to meet the coverage rules.

What FDA approval would change — and what it wouldn't

What it would change

Retatrutide would become legally prescribable, and eligible to be considered for coverage lists.

What it would NOT automatically change

→ Not on the BALANCE list
→ Not in the Bridge
→ Medicaid would not cover it in your state
→ Part D would not cover it for weight loss
→ Your prior authorization not guaranteed
→ Price would not be low

The timing matters. Lilly describes retatrutide as a Phase 3 investigational drug whose availability depends on finishing its trials and clearing regulatory review. Independent industry analysts have projected a possible launch somewhere around 2027 to 2028. Stack the negotiation-and-listing steps on top of that, and realistic Medicare coverage for retatrutide is a 2028-or-later question — at the earliest, and with no guarantees.

The safest way to think about it: Retatrutide could become a future CMS coverage candidate after FDA approval, but no CMS source currently confirms retatrutide coverage under BALANCE, the Bridge, Medicaid, or Part D. Track it through FDA, Lilly, and CMS — not through sellers.

Could Medicaid cover retatrutide under BALANCE?

Not right now. Medicaid coverage under the BALANCE Model depends on whether your state chooses to join, and retatrutide isn't FDA-approved or listed. After approval, Medicaid coverage would still depend on your state joining, retatrutide being added, and you meeting the rules.

The key difference from the Bridge: the Medicare Bridge is nationwide for eligible Part D members, while Medicaid coverage is state-by-state. Medicaid programs can begin joining BALANCE as early as May 2026, but participation is voluntary.

A simple script for your state Medicaid office:

“Does my state Medicaid program take part in the CMS BALANCE Model for GLP-1 coverage? Which GLP-1 medicines are covered for weight management right now, and what are the approval rules?”

For the current state-by-state picture, see our GLP-1 Medicaid coverage by state guide.

If I'm on Medicare, should I wait for retatrutide or use a covered GLP-1 now?

From a coverage standpoint, there's nothing to wait for — retatrutide isn't an option through Medicare today, and won't be for years. Whether you should start a different GLP-1 now is a medical decision for your doctor. But if you qualify for the $50 Bridge or for regular Part D coverage, it's usually far more practical to act than to wait on an uncertain future.

Your situation	What the retatrutide answer means	Best next step
Medicare, want weight-loss coverage	Not covered; Bridge may cover other drugs	Check Bridge eligibility
Medicare + diabetes / sleep apnea / heart disease	Not available; Part D may cover other GLP-1s	Ask your plan about diagnosis-based coverage
Medicaid	Not covered; depends on your state	Check your state's status
Commercial insurance	Not available; FDA-approved options may be covered	Check your formulary
Cash-pay	Not available outside trials	Compare legal FDA-approved options
Already used "research" retatrutide	No coverage path; safety concern	Talk to a clinician honestly

Find your current GLP-1 path — answer a few questions and we'll point you to the route that fits your coverage, timing, and goals.

Find your GLP-1 path →

Can you buy retatrutide online right now?

⚠ No — not legally or safely

Eli Lilly says retatrutide is investigational and available only through Lilly clinical trials, and that any product sold outside those trials is illegal and can't be verified for safety, purity, or dose. Because retatrutide isn't FDA-approved and isn't eligible for legal compounding, websites selling “retatrutide” or “research-grade” peptides are offering an unregulated, unverified substance.

There's no pharmacy oversight, no guarantee of what's in the vial, no correct-dose labeling, and no one accountable if something goes wrong. Medicare and Medicaid will never reimburse a gray-market purchase. Even in the controlled trials, retatrutide's higher doses came with real side effects like nausea, vomiting, and muscle loss — which is exactly why dosing belongs with a real prescriber, not a website.

Warning signs to walk away from

✗"Research use only," but marketed for weight loss
✗No real prescriber involved
✗No FDA-approved labeling
✗No pharmacy verification
✗Claims it's "the same as" Lilly's retatrutide
✗Claims Medicare or Medicaid will pay for it

If you've already used unofficial retatrutide: don't panic, but don't keep guessing either. Talk to a licensed clinician and be honest about what you took, the dose, the timing, and any symptoms. That conversation is worth more than any forum thread.

What are the FDA-approved options if retatrutide isn't covered?

The drugs Medicare can help with are the FDA-approved GLP-1s on the Bridge and BALANCE lists — Foundayo, Wegovy, and Zepbound for weight management, plus others for diabetes and related conditions. Retatrutide isn't one of them. Beginning July 1, 2026, the Bridge will cover Foundayo, Wegovy, and the Zepbound KwikPen for eligible members, while regular Part D may cover certain GLP-1s for covered non-weight-loss uses such as type 2 diabetes, obstructive sleep apnea, certain liver disease, or cardiovascular-risk indications — depending on the drug, your diagnosis, and your plan.

If you're not using Medicare, Medicaid, or another government plan — say you're paying cash or have private insurance and just want a legitimate, FDA-approved GLP-1 you can start now — it makes more sense to compare real brand-name options than to wait on retatrutide coverage that doesn't exist. Ro (sponsored affiliate link, opens in a new tab), for example, carries FDA-approved options including the Zepbound KwikPen, the Foundayo pill, and Wegovy, and offers a free insurance checker.

Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.

Two things to keep straight:

Ro is not the Medicare GLP-1 Bridge — it's a cash-pay and private-insurance program. If your goal is Medicare or Medicaid coverage, the Bridge and your Part D plan are the path, not Ro.
Ro's membership and your medication are billed separately: the Ro Body membership is $39 for the first month, then $149/month (or as low as $74/month on an annual plan paid upfront). The medication is a separate cost — for example, the Foundayo or Wegovy pill runs $149 the first month, then $199–$299.

Check your coverage with Ro's free GLP-1 checker →Compare FDA-approved alternatives →

A compliance note: these FDA-approved brand-name drugs are not the same as retatrutide, and they're not compounded knock-offs. We don't blur those lines.

What we verified for this update

What we checked	What we found	Verified
Retatrutide FDA and legal status	Investigational, Phase 3, available only through Lilly trials	June 1, 2026
Retatrutide trial results	TRIUMPH-1 topline: 28.3% avg weight loss at 80 weeks on 12 mg dose	June 1, 2026
BALANCE drug list and product criteria	9.5% threshold and January 1, 2027 cutoff confirmed	June 1, 2026
Bridge dates, covered drugs, $50 copay, clinical criteria	July 1, 2026 -- Dec 31, 2027; Foundayo, Wegovy, Zepbound KwikPen; $50 flat	June 1, 2026
Bridge extension to December 31, 2027	CMS extended from December 2026; 80% threshold not met for Part D BALANCE	June 1, 2026
Ro pricing	Membership: $39 first month, $149/mo monthly, $74/mo annual. Medication separate.	June 1, 2026

What we did not assume: that retatrutide will be approved, that approval means coverage, that CMS will add it, that any state will cover it, or that online sellers are legitimate.

Frequently asked questions

Quick answers to the questions people search most about retatrutide and CMS coverage.

Is retatrutide FDA-approved?

No. Lilly describes retatrutide as investigational and not FDA-approved as of this update. It is legally available only through Lilly clinical trials.

When could retatrutide become available?

No confirmed FDA approval or launch date has been published. Lilly says availability depends on finishing its Phase 3 trials and clearing regulatory review; independent analysts have projected a possible launch around 2027 to 2028.

Is retatrutide in the CMS BALANCE drug list?

No. The current BALANCE list includes all formulations of Mounjaro, Ozempic, Rybelsus, and Wegovy, the KwikPen formulation of Zepbound, and the Foundayo tablet -- but not retatrutide.

Is retatrutide in the Medicare GLP-1 Bridge?

No. The Bridge covers all formulations of Foundayo and Wegovy and the KwikPen formulation of Zepbound. Retatrutide is not included.

If retatrutide gets FDA approval, will Medicare cover it?

Not automatically. FDA approval is only the first step. CMS, the manufacturer, and participating plans or states would still need to add retatrutide to a coverage pathway, and patients would still need to meet the rules.

Does the Medicare GLP-1 Bridge cover every GLP-1?

No. The Bridge covers only specific listed drugs and formulations. It does not cover every GLP-1, and it does not cover retatrutide.

Can compounded or research retatrutide be covered by Medicare or Medicaid?

No. There is no legitimate Medicare or Medicaid path for unofficial retatrutide. Lilly says retatrutide sold outside its clinical trials is illegal and cannot be verified for safety, purity, or dose.

Could Medicaid cover retatrutide later?

Possibly, but only after FDA approval and only if a state Medicaid program adds it through a coverage pathway. Medicaid participation in the BALANCE Model is state-by-state.

Should I wait for retatrutide?

That is a medical decision, but there is no Medicare coverage path for retatrutide today. If you need treatment now, ask your clinician about FDA-approved options and whether the Bridge, Part D, or Medicaid applies to you.

What happens after the Medicare GLP-1 Bridge ends?

CMS currently says the Bridge runs through December 31, 2027. What comes next depends on whether the longer-term Medicare program launches and which plans and states take part.

Still deciding?

Retatrutide isn't here yet — but real, FDA-approved, often-covered options are. Don't lose months waiting on a drug you can't get when a $50 path may open on July 1, 2026 if you qualify.

Take the free 60-second matching quiz →

Related guides

Sources

Eli Lilly — What to know about retatrutide
Eli Lilly — TRIUMPH-1 Phase 3 topline results
Lilly Medical — Is retatrutide available in the consumer market?
CMS — BALANCE Model
CMS — Medicare GLP-1 Bridge: Information for Beneficiaries
CMS — Medicare GLP-1 Bridge: Information for Providers
KFF Health News — Cheaper GLP-1s through the Medicare Bridge
NPR — Medicare's new GLP-1 option and the $50 copay
Ro — Weight Loss Program Pricing (sponsored affiliate link, opens in a new tab)

The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. We don't provide medical care or coverage decisions. Always confirm current coverage at CMS.gov and with your plan, and talk to a licensed provider about your treatment.

Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.

See our affiliate disclosure for details. Last verified June 1, 2026.